Impressive pivotal trial results suggest an application for the company's troubled candidate is headed to the FDA.
News & Analysis: Stemline Therpeutics
Stemline's lead drug dazzles in a pivotal-stage study, but investors should temper their expectations for the time being.
The clinical-stage oncology company is facing the same hurdles as better-known peers when it comes to next-generation immunotherapy development.
An announcement that its lead candidate might receive an expedited review from the FDA without running additional trials is giving investors a reason to cheer.
A look at what Stemline, KalaBios, and Tetraphase have accomplished in their first year as public companies.
Therapeutics ruled the world of health-care this week -- with Chelsea, PTC, and Stemline coming out on top and Sarepta and Cell not far behind.
Aratana Therapeutics Inc., Receptos Inc., and Stemline Therapeutics Inc. are three biotech IPOs of 2013 that are finishing the year with strong gains. Can they continue soaring into 2014?
Are these three stocks sells or belles? You be the judge!
Ben Bernanke's words didn't hurt these three stocks this week.
A lot of companies went public last month.